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Conflicts of Interest in Dermatology: 
More than Skin Deep?
Acta Dermatologica Venereologica recent-ly published a special report that summa-rizes a workshop held in Finland by the 
European Academy of Dermato-Venereology 
celebrating the elevation to higher conscious-
ness of “conflicts of interest (COI)” in cutane-
ous medicine (Williams et al., 2006). The report 
first defines COI metaphorically: dermatolo-
gists with COI have metamorphosed into dogs 
and other dermatologists and patients into cats. 
Not all dogs chase cats, but, because some do, 
cats must take notice. Through disclosure by 
journals, professional meetings, and educa-
tional events, the cats can be wary of the dogs. 
Evidently they are, because the report cites two 
British Medical Journal studies that polled read-
ers to determine their enthusiasm for a paper 
describing a clinical study in which half the 
respondents were told that the study’s authors 
had financial conflicts and half that they did 
not. The readers rated the fictionally unconflict-
ed version slightly (but statistically significantly) 
more interesting, important, and believable than 
the conflicted one. The report echoes editors of 
high-profile general medical journals in decry-
ing “a cycle of dependency between physicians, 
academic opinion leaders, patient’s organiza-
tions, researchers and industrial interests,” cit-
ing a dismal litany of deceptive industry-based 
“disease-mongering” and marketing practices. It 
calls for adherence to medical journal editors’ 
demands for prospective trial preregistration, 
since industry-sponsored research publica-
tions sometimes give rosier views of products 
than FDA filings and package inserts. It indicts 
“ghost writing” of papers, whether by academic 
or company employees, and praises recently 
toughened disclosure policies of the Journal of 
the American Medical Association.
The report concludes by expressing “a ray of 
hope” that now disease-mongering and ghost 
writing are part of the dermatologist’s vocabulary 
and asks for “unbiased summaries” to evaluate 
clinical trials. It endorses a proposal to curtail 
sharply the presence of companies in academic 
health centers by banning gifts, samples, and 
meals and by collectivizing corporate support of 
research and education. The aim is not to “dis-
courage a flourishing and innovative healthcare 
industry” but to prevent dermatologists from los-
ing “values on which the . . . profession is built.”
Given that 20 years of unopposed airtime has 
sensationally covered real and alleged industrial 
transgressions and popularized COI, the idea 
that dermatologists have somehow failed to rec-
ognize it hitherto seems strange. Space does not 
permit addressing all the workshop’s points in 
detail, so I have selected a few.
The canine–feline depiction of COI illustrates 
two important points. First, it shows how COI 
has escalated from its dictionary definition—a 
conflict—to an outcome—a potentially preda-
tory situation. Second, I have no idea what per-
centage of dogs chase cats, but I imagine that 
it is high, far higher than that of documented 
cases in which COI have adversely affected 
dermatologic practice. Disclosure and transpar-
ency are reasonable goals to a point. However, 
all disclaimers to the contrary, disclosure has 
actually become a disrespectful ad hominem 
assault, meant primarily not to honor sponsor-
ship but to discount scholars’ word and work. 
The empiric studies reported in the BMJ bring 
this point home. The prurient focus on who 
pays whom how much, rather than on the 
scientific data, is characteristic of the COI litera-
ture. A bizarre aspect of the current COI disclo-
sure requirements is that they exempt medical 
financial interactions that do not involve drug or 
device companies—around 85% of total health-
care expenditures.
We want scientific rigor in dermatology, but 
the arguments to make the case for the dam-
ages of COI violate such rigor. Based on anec-
dotes, they lack context, namely a comparison of 
adverse outcomes or bias concerns to noncom-
mercial interactions of physicians and scientists 
(Stossel, 2005). Finally, the real damage inflicted 
by the ambient obsession with COI has been 
the prevention of company startups by overly 
restrictive university COI regulations and a total 
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consulting ban inflicted since 2005 on intramural NIH 
researchers, which adversely affects retention and recruit-
ment of researchers and prevents companies from getting the 
best advice. The idea that “objective” guidelines somehow can 
relieve dermatologists from the uncertainties they face making 
difficult clinical decisions is a conceit. “Unconflicted” usu-
ally means less competent, and advisories composed of such 
individuals empirically make bad recommendations. For exam-
ple, an unconflicted Institute of Medicine panel recommended 
removal of mercurial preservatives from vaccines because of 
litigious claims unsupported by numerous comprehensive 
studies that they contributed to autism. The recommendation 
caused deaths due to failure to vaccinate and a reduction in 
commercial vaccine production (Stratton et al., 2001).
Finally, the risks of economic incentives and COI sum-
marized in the workshop are distortions. The uncontestable 
fact is that medicine in general and dermatology in particular 
improve steadily, not because of medical ethics and profes-
sionalism but because of products developed by private com-
panies, capitalizing to some extent on knowledge acquired 
from academic research. What is far more important for der-
matologists to understand than the inflated risks of COI are 
the mechanisms by which industry accomplishes these feats 
and the difficulties it must address to do so (Epstein, 2006), 
factors that the critics have no experience with and therefore 
treat dismissively. The greater presence of business in medi-
cine today is not a commercial conspiracy but an evolution-
ary adaptation to opportunity (Stossel, 2007). The monies that 
industry contributes to education and research mean more of 
these activities take place. If dermatologists cannot sort out 
promotion from substance, it is the fault of their character, 
their training programs, or both—not of companies.
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